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In less than 10 years, the number and importance of non-
surgical treatment modalities in patients with colorectal
cancer (CRC) have increased dramatically, both in the
adjuvant and the advanced settings. However, despite the
improvement of cytotoxic therapy in CRC, many patients
still develop progressive disease and unfortunately in
patients with disease resistant to 5-ﬂuorouracil/folinic
acid, irinotecan and oxaliplatin, no effective cytotoxic
therapy is known. The rapidly expanding knowledge in
tumor biology has encouraged optimism for the possibility
to ﬁnd and target tumor-speciﬁc mechanisms and thereby
increase both efﬁcacy and tolerance. A great number of
‘targeted drugs’ are being tested in clinical trials and some
of these new drugs, like bevacizumab, cetuximab and
panitumumab, are available for routine use in health care.
These new targeted drugs will expand the therapeutic
arsenal in CRC to a great extent, but they will also add to
the complexity of treatment of CRC. In this review, we
summarize the current status of antibody therapy in
patients with CRC.
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Introduction
In less than 10 years, the number and importance of
non-surgical treatment modalities in patients with
colorectal cancer (CRC) have increased dramatically,
both in the adjuvant and the advanced settings. A
decade ago, treatment options were dominated by
injections of 5-ﬂuorouracil (FU) modulated by folinic
acid (FA), but presently routinely combined with
irinotecan or oxaliplatin.
Despite the improvement of cytotoxic therapy in
CRC, many patients still develop progressive disease;
and unfortunately in patients with disease resistant to
FU/FA, irinotecan and oxaliplatin no effective cytotoxic
therapy is known. The rapidly expanding knowledge in
tumor biology has encouraged optimism for the
possibility to ﬁnd and target tumor-speciﬁc mechanisms
and thereby increase both efﬁcacy and tolerance. A
great number of ‘targeted drugs’ are being tested in
clinical trials and some of these new drugs are already in
the market and available for routine use in health care.
In patients with metastatic CRC (mCRC), two
antibodies were approved in USA and EU in 2004 and
are now being used in daily practice; cetuximab (Cx)
(Erbitux), a monoclonal antibody (mAb) blocking the
epidermal growth factor receptor (EGFR), and bevaci-
zumab (Bv) (Avastin) a mAb targeting angiogenesis.
Very recently, panitumumab (Pa) (Vertibix), a new
antibody against EGFR has been approved. These new
targeted drugs expand the therapeutic arsenal in CRC to
a great extent, but they will also add to the complexity
of treatment of CRC.
In this review, we summarize the current status of
antibody therapy in patients with CRC. To better
understand the clinical role of these antibodies, espe-
cially since they are to be combined with chemotherapy,
we consider it necessary also to run through the current
principles of chemotherapy in mCRC.
Principles for retrieval of data
To identify data on antibody therapy in patients with
CRC, we searched the databases Medline and Clinical-
Trials.gov for relevant publications using the search
terms colon cancer, colorectal cancer, antibody therapy,
monoclonal antibody, targeted therapy, cetuximab, bev-
acizumab, panitumumab and edrocolomab. Data on
antibodies were also identiﬁed in relevant publications
and from listings in recent overviews (Veronese
and O’Dwyer, 2004; Nygren et al., 2005; Stern and
Herrmann, 2005; Arnold et al., 2006; Saunders and
Iveson, 2006; Van Cutsem et al., 2006). Full reporting of
ﬁnal results from important clinical trials often lags
behind more preliminary reports in the abstract form.
Therefore, we included data from abstracts to be able to
present the most recent information on antibody
therapy. Abstracts presented at the annual meetings of
ASCO, ASCO GI, AACR, ECCO/ESMO from 2004 to
2006 were reviewed and included as applicable. In this
review, we will summarize the clinical status of antibody
therapy in mCRC but only antibodies that have been
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evaluated in large phase II or phase III studies or large
observational studies.
Palliative chemotherapy in patients with mCRC
FU and FA
For almost 50 years, FU with or without FA has been
the most extensively used chemotherapy regimen for
patients with CRC, both as adjuvant and palliative
treatment (Ragnhammar et al., 2001; Meyerhardt and
Mayer, 2005). Untreated only half of the patients with
mCRC will be alive after 6 months and survival past 2
years is rarely seen. FU/FA induced tumor regression
(completeþ partial response) in 20% of patients, pro-
longed median survival from 6 to 12 months and
improved quality of life (Ragnhammar et al., 2001).
However, most patients developed progressive disease
after median 4–6 months and there were no effective
salvage therapies available for patients with progressive
disease following FU/FA treatment. Many different
schedules of FU with different doses of FA have been
developed and numerous studies have been conducted to
establish the optimal FU/FA regimen, but without
reaching consensus. FU has been given as a continuous
infusion, as prolonged infusion (24–48 h), as a bolus
injection (1–5 consecutive days) or as a combination of
both (Ragnhammar et al., 2001; Meyerhardt and
Mayer, 2005).
In the United States, the Mayo regimen (bolus on ﬁve
consecutive days, repeated every 4 weeks) used to be the
standard regimen for many years and served as
comparison with newer regimens. Randomized trials
have shown that infusional administration of FU/FA
improves the tumor response rate (RR), increases time
to tumor progression (TTP – in this review, we will
make no distinction between TTP and progression-free
survival) and marginally improves overall survival (OS)
at reduced or similar toxicity (de Gramont et al., 1997;
Ko¨hne et al., 2003), and the Mayo regimen should not
be used anymore. In many parts of Europe, and
increasingly in United States, modulated infusion regi-
mens are preferred; the most commonly used approach
is probably the ‘de Gramont’ regimen that combines
FA, bolus FU and prolonged infusion FU (de Gramont
et al., 1997; Ragnhammar et al., 2001; Meyerhardt and
Mayer, 2005).
Other bolus regimens are better tolerated than the
Mayo regimen. The Nordic FU/FA bolus schedule (FU/
FA administered on days 1 and 2 every 2 weeks) can
easily be combined with oxaliplatin (FLOXNordic) or
irinotecan (FLIRINordic), and phase II (Sorbye et al.,
2004) and III studies (Glimelius et al., 2005) have
already shown that these regimens are valid alternatives
to other combination regimens.
Randomized studies have also shown that oral
therapy with tegafur/uracil (UFT) and FA (Carmichael
et al., 2002; Douillard et al., 2002) or capecitabine (Van
Cutsem et al., 2004) is as effective as bolus FU/FA
therapy and with comparable or less toxicity.
First-line combination chemotherapy
The new era of combination chemotherapy started when
it was shown that irinotecan as single agent increases the
median OS by 3 months in patients resistant to FU/FA
(Cunningham et al., 1998; Rougier et al., 1998)
compared with best supportive care (BSC) or infusional
FU/FA. Comparable results can be obtained with a
combination of FU/FA and oxaliplatin (Pitot et al.,
2005). There is no strong rationale for combining FU/
FA and irinotecan in this setting as opposed to the
strong synergy observed with oxaliplatin and FU/FA
(Starling and Cunningham, 2005).
The introduction of doublets (FU/FA or oral therapy
in combination with irinotecan or oxaliplatin) as ﬁrst-
and second-line therapy has increased the life expec-
tancy considerably, almost half of the patients are alive
after 2 years and the chance of long-term survival still
continues to increase (Ragnhammar et al., 2001;
Rothenberg et al., 2003; Grothey et al., 2004; Meyer-
hardt and Mayer, 2005).
First-line doublet (Tables 1 and 2) increases RRs
(from 20 to almost 50%) and prolongs time to
progression (TTP) from 4–6 months to 6–8 months
(Ragnhammar et al., 2001; Meyerhardt and Mayer,
2005). In some studies, doublets increased RR rate and
prolonged TTP, whereas signiﬁcant prolongation of OS
was not seen, probably due to crossover at the time of
progressive disease (PD) and the use of effective second-
line therapy (de Gramont et al., 2000; Giacchetti et al.,
2000).
Direct comparisons between combinations (Tables 1
and 2) with irinotecan (i.e. FOLFIRI or XELIRI) and
oxaliplatin (i.e. FOLFOX or XELOX) show that most
doublets are equally effective with respect to RR,
median TTP and median OS (e.g. Grothey et al., 2003;
Tournigand et al., 2004; Cassidy et al., 2006; Kubicka
et al., 2006), however, only in studies in which identical
ﬂuoropyrimidenes were used (Goldberg et al., 2004).
The general notion at present is that the choice of
doublet is mainly a matter of the adverse effects proﬁle
that differs between these combinations, but IFL (bolus
schedule of irinotecan in combination with ﬂuorouracil
and leucovorin primarily tested in North America) is too
toxic and less active than other regimens and therefore
obsolete and should not be offered anymore.
Table 1 Abbreviation of the most common chemotherapy regimens
in patients with CRC
FU/FA regimen
Bolus Infusion Capecitabine UFT/FA
Oxaliplatin FLOXnordic
FLOXUS
bFOL
FOLFOX
FUFOX
XELOX or
CAPOX
TEGAFOX
Irinotecan FLIRI
IFL
FOLFIRI XELIRI or
CAPIRI
TEGAFIRI
Abbreviations: CRC, colorectal cancer; FA, folinic acid; FU, 5-
ﬂuorouracil.
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Duration of combination chemotherapy
When FU/FA was the only treatment available, it was
natural to continue therapy as long as the disease was
controlled without any sign of progression. With the
introduction of doublets, this strategy was maintained
and chemotherapy was administered until tumor pro-
gression, but this strategy now has to be revised. One
reason is the patients need for ‘drug holidays’ in light of
the cumulative toxicity resulting from the above
strategy. Another, and more important, reason is that
recent studies have shown that an intermittent strategy
compared with continuous use of chemotherapy
does not compromise efﬁcacy (Labianca et al., 2006;
Maindrault-Goebel et al., 2006) and a ﬁnal reason is
a reduced cost of treatment. Thus, in patients with
non-progressive mCRC after, for example, 4 months of
combination chemotherapy, a break in therapy can
safely be recommended, assuming that a close surveil-
lance is offered and followed by treatment re-introduc-
tion or change to another regimen upon tumor
progression.
Second-line therapy
Second-line therapy after ﬁrst-line doublet generates
RRs of 5–20%, increases TTP to 4–6 months (Rothen-
berg et al., 2003; Grothey et al., 2004; Kemeny et al.,
2004; Tournigand et al., 2004; Pfeiffer et al., 2006) and
also adds to a prolonged OS. A recent review pointed
out that OS was signiﬁcantly correlated with the
Table 2 Important randomized studies evaluating chemotherapy in patients with mCRC
Author (publication regimens) No. of patients RR (%) Median TTP (months) Median OS (months)
5-FU/FA vs combination with irinotecan
Saltz et al. (2000)
Bolus 5-FU/FA 226 21 4.3 12.6
IFL 231 39a 7.0a 14.8a
Douillard et al. (2000)
Infusion 5-FU/FA 187 22 4.4 14.1
FOLFIRI 198 35a 6.7a 17.4a
Ko¨hne et al. (2003)
Infusion 5-FU/FA 216 32 6.4 16.9
FUFIRI 214 54a 8.5a 20.1a
5-FU/FA vs combination with oxaliplatin
de Gramont et al. (2000)
Infusion 5-FU/FA 210 22 6.2 14.7
FOLFOX 210 51a 9.0a 16.2
Giacchetti et al. (2000)
Infusion 5-FU/FA 100 12 6.1 19.9
FOLFOX 100 34a 8.7a 19.4
Grothey et al. (2002)
Bolus 5-FU/FA 124 23 5.3 16.1
FUFOX 118 48a 7.9a 20.4a
Combination vs combination
Tournigand et al. (2004)
FOLFOX 111 54 10.9 20.6
FOLFIRI 111 56 14.2 21.5
Grothey et al. (2003)
CAPOX 82 51 7.9 >16
CAPIRI 79 43 7.9 >16
Kubicka et al. (2006)
FUFOX 234 50 8.0 18.1
CAPOX 242 47 7.0 16.6
Goldberg et al. (2004)
IFL 264 31 6.9 15.0
FOLFOX 267 45a 8.7a 19.5a
Glimelius et al. (2005)
FLIRINordic 282 — 9.5 18.2
FOLFIRI 274 — 9.0 17.8
Abbreviations: FA, folinic acid; FU, 5-ﬂuorouracil; mCRC, metastatic colorectal cancer; OS, overall survival; RR, response rate; TTP, time to
progression. aSigniﬁcant difference.
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percentage of patients who received all three drugs
(Grothey et al., 2004). In a recent update, they
demonstrated that a strategy of making all three active
agents available was more important than the use of
doublet upfront (Grothey and Sargent, 2005). Never-
theless, patients who received ﬁrst-line chemotherapy
doublets had a greater chance to receive all three agents
in the course of their therapy and they concluded that in
clinical practice doublet should remain the standard of
care for ﬁrst-line treatment of patients with advanced
CRC.
Third-line therapy
Thus, many patients have received different combina-
tions of FU/FA, irinotecan and oxaliplatin as ﬁrst- and
second-line (and occasionally third line) therapy for
mCRC. Despite progressive disease, many patients are
still in an excellent performance and there is deﬁnitely a
need for further effective regimens with the capability to
postpone further progression of the disease, induce
remissions, prolong life and improve quality of life.
Only very few studies on ‘third-line’ chemotherapy in
patients pretreated with FU/FA, irinotecan and oxali-
platin have been published (Rosati et al., 2003; Lim
et al., 2005). Rosati et al. (2003) treated 21 patients with
raltitrexed and mitomycin-C but no patient had tumor
regression, and median survival was only 5 months. Lim
et al. (2005) also treated 21 patients but with a
combination of capecitabine and mitomycin-C. Only
one patient had tumor regression, TTP was 2.6 months
and OS was 6.5 months and they concluded that the
regimen did not add to increasing patients OS.
Thus it seems as if the improvement in OS has reached
a limit of around 18–21 months and even if all patients
are exposed to all three drugs, either sequentially or
concomitantly, it is not expected that the OS can be
prolonged beyond 24 months (Grothey et al., 2004;
Falcone et al., 2006; Souglakos et al., 2006).
Targeted drugs in CRC
During the last decade, there has been major scientiﬁc
progress in the understanding of cancer biology
(Hanahan and Weinberg, 2000) and as a consequence,
a large number of new potential targets for medical
treatment have been identiﬁed. A number of appro-
aches, from small molecules to antibodies (Nygren et al.,
2005), can inhibit this signal transduction and thus slow
down the growth of malignant cells. These new agents
are often designated as ‘targeted drugs’ and very
encouraging results have been obtained if administered
with combination chemotherapy. The use of monoclo-
nal antibodies have moved into the routine health care
of patients with mCRC, and in recent years a huge
number of patients have received antibodies often in
combination with chemotherapy (Nygren et al., 2005;
Arnold et al., 2006).
At least ﬁve antibodies have been studied extensively
in patients with CRC. Two antibodies – edrocolamab
(Punt et al., 2002) and 3H1 (Chong et al., 2006) – were
tested in the adjuvant and the metastatic settings,
respectively, but without improvements of survival,
and there is presently no indication for treatment with
edrocolomab or 3HI outside clinical trials.
Three antibodies – Bv, Cx and Pa – have shown
clinical relevant efﬁcacy in clinical trials and the
following sections will summarize the data on their
clinical efﬁcacy and safety. Large clinical trials investi-
gating their potential roles in the adjuvant setting are
ongoing, but no data are yet available and therefore the
following sections will only address patients with
mCRC.
Monoclonal antibodies for treatment of mCRC
Efﬁcacy and safety of Bv in mCRC
Angiogenesis plays an important role in cancer because
tumor growth beyond 1–2mm depends on new blood
vessels for supply of nutrients and oxygen. Vascular
endothelial growth factors (VEGF’s), pro-angiogenic
factors, are the most important regulators of angio-
genesis and has been detected in a range of malignant
tumors, including CRC.
Excess VEGF from tumor or normal stromal cells
leads to activation of endothelial cell proliferation,
migration and survival but also to increased vascular
permeability and increased interstitial pressure.
Bv is a humanized mAb which prevents binding of
VEGF-A to the VEGF receptors. The terminal elimina-
tion half-life is approximately 21 days and does not
induce antibodies to Bv (Ferrara, 2004). Inactivation of
VEGF will lead to normalization of tumor vessels,
decreased interstitial pressure and allow a more efﬁcient
delivery of chemotherapy to tumor cell (Ferrara, 2004;
Willett et al., 2004; Hicklin and Ellis, 2005).
First-line therapy
In a small randomized phase II study (AVF 0780) with
104 patients (Table 3), the goal was to investigate
efﬁcacy and safety of Bv in combination with FU/FA
(Kabbinavar et al., 2003). Three groups of patients
received FU/FA alone, FU/FA in combination with
low-dose Bv (5mg/kg every 2 weeks) or high-dose Bv
(10mg/kg every 2 weeks). Patients receiving low-dose Bv
had the highest RR (40%) and longest TTP (9.0
months) and logically low-dose Bv was recommended
for further studies.
A retrospective analysis of this trial (Kabbinavar
et al., 2005) suggested that Bv was particularly effective
in patients with poor prognostic features ((performance
status (PS) 1–2, age >65 years, and low serum albumin).
In contrast, retrospective analyses of studies demon-
strating the beneﬁt of adding irinotecan to FU/FA
(Douillard et al., 2000; Saltz et al., 2000) suggested that
the beneﬁt derived from irinotecan might be limited to
patients with a good performance status. In addition,
there was a tendency to increased toxicity in elderly
patients, poor performance, low serum albumin or prior
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pelvic radiotherapy. Therefore, two subsequent rando-
mized trials (Table 3) of Bv were planned and
conducted. In the pivotal phase III trial, AVF2107
(Hurwitz et al., 2004) Bv was added to IFL (standard
combination chemotherapy in US when the study was
launched) in good performance patients (PS 0 or 1). A
supportive randomized, phase II trial (AVF 2192) was
run concurrently in patients considered non-optimal
candidates for ﬁrst-line irinotecan-containing regimens
(Kabbinavar et al., 2005).
In AVF2107, 925 patients were randomized to bolus
FU/FA and irinotecan (IFL) or IFL in combination
with low-dose Bv (Hurwitz et al., 2004). Initially a third
arm with FU/FAþBv was included but terminated
after inclusion of 110 patients following a planned safety
analysis. Patients were allowed to receive further
chemotherapy, but not to crossover to Bv. Approxi-
mately half the patients in both treatment groups
(Hedrick et al., 2004) received second-line therapy but
nonetheless OS was signiﬁcantly prolonged (from 15.6
to 20.3 months). This improvement was observed in the
subgroup receiving oxaliplatin as second-line treatment
(25 vs 22 months) as well as in patients who did not
receive oxaliplatin (20 vs 16 months).
In AVF 2192 (Kabbinavar et al., 2005), 209 patients
who were not suitable for irinotecan received FU/FA
and placebo or FU/FA combined with low-dose Bv
(Table 3). The addition of Bv signiﬁcantly prolonged
TTP (from 5.5 to 9.2 months) but RR (15 vs 26%)
and OS (12.9 vs 16.6 months) were not improved
signiﬁcantly. The lack of difference in median OS may
be due to the small number of patients but post-
progression therapy, which hampers the interpretation
of OS, might be another explanation. TTP is unaffected
by second-line therapy and for that reason TTP may be
a more representative measurement of the clinical
beneﬁt provided by new regimens.
OS was signiﬁcantly prolonged only in AVF 2107, but
the overall impression from the published phase II and
III studies (Table 3) was that addition of Bv to FU/FA
alone as well as to doublet prolong TTP with 3–4
months and OS with 4–6 months. Although addition of
Bv constantly improved outcome in ﬁrst-line treatment,
data are only coming from what might be called
‘mediocre chemotherapy regimen’. The question there-
fore is whether Bv also will add to the efﬁcacy of
‘optimal chemotherapy regimens’.
Two recently randomized phase II studies (TREE and
BICC-C) were presented at the oral session of the 2006
colorectal ASCO program (Table 3). Both studies were
initiated to establish the optimal combination of
chemotherapy but they were cut short secondary to
the availability of Bv. In TREE-1 (Hochster et al., 2006),
three different ﬂuoropyrimidine–oxaliplatine regimens
(FOLFOX, bFOL or XELOX) were compared. Only
150 patients were randomized and no major differences
in activity were observed but bFOL was the least
efﬁcacious (in relation to RR and TTP). In TREE-2
(Hochster et al., 2006), low-dose Bv was added to the
three regimens. In a cross-trial comparison with the
Table 3 Most important studies with Bv in patients with mCRC
Author Regimen Phase n RR (%) TTP (months) OS (months)
First-line therapy
Kabbinavar et al. (2003) FUFA II 36 17 5.2 13.8
AVF 0780 FUFA+BvLD 35 40
a 9.0a 21.5
FUFA+BvHD 33 24 7.2 16.1
Hurwitz et al. (2004) IFL III 411 35 6.2 15.6
AVF 2107 IFL+BvLD 402 45
a 10.6a 20.3a
FL+BvLD (110) (40) (8.8) (18.3)
Kabbinavar et al. (2005) FUFA II 105 15 5.5 12.9
AVF 2192 FUFA+BvLD 104 26 9.2
a 16.6
Hochster et al. (2006) mFOLFOX II 50 43 8.7 19.2
TREE-1 bFOL 50 22 6.8 17.9
mXELOX 50 35 5.9 17.2
TREE-2 mFOLFOX+BvLD II 75 53 9.9 26.0
bFOL+BvLD 74 41 8.3 20.7
mXELOX+BvLD 74 48 10.3 27.0
Fuchs et al. (2006) FOLFIRI II 144 47 7.6a 23.1
BICC-C period 1 mIFL 141 42 5.8 17.5
XELIRI 145 38 5.5 18.9
BICC-C period 2 FOLFIRI+BvLD II 57 54 9.9 NR
a
mIFL+BvLD 60 53 8.3 18.7
Cassidy et al. (2006) XELOX or FOLFOX III 700 — 8.0 —
NO 16966 XELOX or FOLFOX+BvLD 700 — 9.4
a —
Second-line therapy
Giantonio et al. (2005) FOLFOX III 292 9 4.8 10.8
E3200 FOLFOX+BvHD 293 22
a 7.2a 12.9a
Abbreviations: Bv, bevacizumab; BvHD, high-dose Bv (10mg/kg); BvLD, low-dose bevacizumab (5mg/kg); mCRC, metastatic colorectal cancer;
NR, not reached yet; OS, overall survival; RR, response rate; TTP, time to progression. aSigniﬁcant difference.
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former TREE-1 trial (identical oxaliplatin regimens
without Bv), the RRs were higher and OS was
prolonged from 18.2 to 24.4 months.
The BICC-C (Fuchs et al., 2006) was a parallel study.
In the ﬁrst part, patients were randomized to three dif-
ferent ﬂuoropyrimidine–irinotecan regimens (FOLFIRI,
modiﬁed IFL or XELIRI with a second randomi-
zation to plus/minus celecoxib). TTP was superior for
FOLFIRI compared with either of the other two
regimens, there was a trend in OS in favour of
FOLFIRI, and toxicity also favored the FOLFIRI
arm. In the second part of the trial, OS was signiﬁcantly
prolonged for FOLFIRI plus low-dose Bv compared to
IFL plus low-dose Bv (Table 3). Cross-trial comparison
between part 1 and 2 of BICC-C suggested that addition
of low-dose Bv prolonged OS.
However, these data must be interpreted with some
precaution due to the method of a cross-trial compar-
ison, and therefore ﬁnal results of NO16966 (FOLFOX
vs XELOX, with or without Bv) and a US trial
(mFOLFOX6 with or without Bv) are awaited with
impatience and the ﬁrst data were recently presented
(Cassidy et al., 2006).
NO16966 (Table 3) was initiated to compare FOL-
FOX and XELOX and from June 2003 to May 2004,
614 patients were randomized. After approval of Bv, it
was very difﬁcult to continue with chemotherapy alone
and therefore the protocol was amended to a two-by-
two placebo-controlled study where patients were rando-
mized to XELOX or FOLFOX4 and low-dose Bv or
placebo (additionally 1400 patients). The main end point
was TTP and the two primary objectives were to establish
that XELOX was not inferior to FOLFOX and that
chemotherapy plus Bv was superior to chemotherapy
plus placebo. In more than 2000 patients, XELOX was
not inferior to FOLFOX (TTP 8.0 vs 8.5 months) and the
safety proﬁles were balanced. In the second part of the
study, the ﬁrst evidence that Bv adds beneﬁt to ﬁrst-line
oxaliplatin-based chemotherapy was presented. The
overall safety proﬁle was in line with previous studies.
TTP was signiﬁcantly prolonged (TTP 8.0 vs 9.4 months).
Hopefully, this improvement will translate into a clinic-
ally meaningful improvement in OS but before making
ﬁnal conclusions we must await data on OS.
Second-line therapy
After publication of the Saltz study (Saltz et al., 2000),
IFL became the standard treatment in US for ﬁrst-line
treatment. In a phase III study (Rothenberg et al., 2003),
it was established that FOLFOX added to OS as second-
line therapy after ﬁrst-line therapy with irinotecan. It
was therefore natural to assess second-line oxaliplatin in
combination with Bv. In the important ECOG E3200
phase III study, 829 patients previously treated with
FU/FA and irinotecan were randomized to receive
FOLFOX alone, FOLFOX in combination with high-
dose Bv or high-dose Bv alone (Giantonio et al., 2005).
The Bv alone arm was closed by the data monitoring
committee after an interim analysis in 244 patients
suggested low activity (RR 3% and TTP 2.7 months).
High-dose Bv and FOLFOX signiﬁcantly improved
RR, TTP and OS (Table 3). The survival beneﬁt was
observed in subgroups deﬁned by age (o65 vs >65
years) and gender.
The combination of FU/FA and low-dose Bv was also
evaluated in patients progressing after irinotecan and
oxaliplatin-based regimens (third-line therapy), but an
investigator RR of only 4% (independent conﬁrmed
1%) and an median TTP of 3.7 months indicated very
limited activity of this combination in this setting (Chen
et al., 2006).
On 26 February 2004, FDA (US Food and Drug
Administration) approved Avastin (Bv) in combination
with intravenous (i.v.) ﬂuorouracil-based chemotherapy
as a ﬁrst-line treatment for patients with mCRC and on
20 June 2006, FDA granted approval for a labeling
extension for Avastin, with i.v. FU-based chemother-
apy, for the second-line treatment of mCRC.
In Europe, Bv was granted marketing authorization
by the European Medicines Agency (EMEA) on 13
January 2005 with the approved indication ‘Avastin
(bevacizumab) in combination with intravenous 5-
ﬂuorouracil/folinic acid or intravenous 5-ﬂuorouracil/
folinic acid/irinotecan is indicated for ﬁrst-line treat-
ment of patients with mCRC’.
Do the prognostic characteristics of patients included in
trials reﬂect those of patients in routine health care?
In a large, observational study (BRiTE) of almost 2000
patients (Kozloff et al., 2006), the objective was to
estimate TTP and OS in less-selected patients receiving
Bv plus ﬁrst-line chemotherapy at the physician’s
discretion (63% oxaliplatin regimens, 24% irinotecan
regimens). Estimated TTP (10.2 months) was compar-
able to that observed in AVF2107 with no difference
between irinotecan and oxaliplatin regimens, but OS
was not yet estimable.
In a parallel community-based study enrolling almost
2000 patients (First BEAT), the safety proﬁle of Bv in
combination with ﬁrst-line chemotherapy regimens at
physician’s choice (48% oxaliplatin regimens, 33%
irinotecan regimens) was also found to be consistent
with that observed in other studies (Kozloff et al., 2006;
Van Cutsem et al., 2007a).
Toxicity to Bv
Treatment with Bv is generally well tolerated and does
not enhance the speciﬁc chemotherapy toxicity. The
most dangerous adverse events associated with Bv are
thrombo-embolic complications, gastro-intestinal per-
foration and wound healing complications, but bleed-
ing, hypertension and proteinuria are also seen.
Initial evaluation of toxicity suggested an increased
risk of any thrombo-embolic event, but detailed analysis
of data from the randomized studies (Novotny et al.,
2004) and from large observation studies with over 3800
patients (Kozloff et al., 2006; Van Cutsem et al., 2007)
showed a two- or three-fold increase but only in arterial
thrombo-embolic events. These ﬁgures were conﬁrmed
in a pooled analysis of data from ﬁve randomized trials
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in patients with lung cancer, breast cancer or CRC
(Skillings et al., 2005). The addition of Bv to
chemotherapy increased the risk of arterial thrombo-
embolic complications (from 1.7 to 3.8%) – especially in
patients with cardiovascular risk factors and age X65
years.
GI-perforation is a life-threatening but fortunately
uncommon complication observed in around 1% of
patients (often within the ﬁrst 60 days of treatment)
treated with Bv (Hurwitz et al., 2004; Kozloff et al.,
2006; Kretzschmar et al., 2006; Sugrue et al., 2006).
The risk of bleeding is twofold increased (approxi-
mately 4 vs 2%), but Bv did not increase hemorrhagic
complications in patients receiving low-dose aspirin
(Hambleton et al., 2005) or even full-dose anticoagula-
tion (Hambleton et al., 2004). A common side effect is
hypertension. In the randomized studies (Kabbinavar
et al., 2003, 2005; Hurwitz et al., 2004), severe
hypertension grade 3/4 occurred in approximately
10% of patients but was easily managed with oral
medication in most cases. Proteinuria may be seen but
grade 3 or 4 is unusual.
What is the optimal dose and what is the optimal duration
of therapy with Bv?
No published study has been adequately powered to con-
clude a dose–response relationship (Lyseng-Williamson
and Robinson, 2006). In AVF 0780, patients receiving
low-dose Bv (5mg/kg every 2 weeks) had the highest RR
(40%) and longest TTP (9.0 months) and logically low-
dose Bv was recommended for further studies.
A few studies have used Bv 10mg/kg in patients with
mCRC (Giantonio et al., 2005, 2006a) but, to our
knowledge, without substantial argument for this
doubling of dose. Interestingly, in E3200, a sizeable
number of patients needed protocol-speciﬁed dose
reductions of Bv to 5mg/kg, and TTP and OS were
not compromised for patients who underwent dose
reduction (Giantonio et al., 2006b).
In a small breast cancer study, patients received (not
randomized) Bv monotherapy at three different dose
levels: 3mg/kg (18 patients: RR 5.6%, OS 14.0 months),
10mg/kg (41 patients: RR 7.3%, OS 12.8 months) or
20mg/kg (16 patients: RR 6.3%, OS 7.6 months) every 2
weeks. The optimal dose of Bv was determined to be
10mg/kg but this type of data does not allow any
comparison or conclusion (Lyseng-Williamson and
Robinson, 2006).
In most studies, patients continued Bv until progres-
sion or unacceptable toxicity. No data have been
presented yet justifying the continued use of Bv beyond
PD in combination with some other chemotherapeutic
regimen.
Since the introduction of Bv in phase I studies, the
ﬁrst dose of Bv had been given over 90min; the second
dose over 60min and subsequent doses over 30min. At
MSK Cancer Center, non-protocol infusion times of Bv
were gradually reduced and since November 2005, Bv at
5mg/kg was given over 10min without serious hyper-
sensitivity reactions (Saltz et al., 2006).
Predicting efﬁcacy of Bv
Treatment with Bv is cost-intensive and thus, it is very
imported to identify predictive factors (clinical, serolo-
gical or tissue). For patients treated in AVF 2107,
subgroup analysis showed prolonged OS for patients
treated with IFL plus Bv regardless of clinical char-
acteristics at baseline (Fyfe et al., 2004). Patients with an
increased level of baseline plasma-VEGF had a shorter
median OS, but the survival beneﬁt of treatment with Bv
was independent of baseline plasma-VEGF (Holden
et al., 2005).
Other subset analysis evaluated microvessel density
(MVD) and expression of VEGF and thrombospondin-
2 on archival tumor tissue from almost 300 patients, but
Bv improved survival regardless of the level of VEGF,
thrombospondin-2 or MVD (Jubb et al., 2006). Finally,
tumor tissue from 295 patients was analysed for
mutations in k-ras, b-raf or p-53 and expression of
p53, but none of these factors could predict median OS
and Bv improved survival in all subgroups (Ince et al.,
2005).
Antibodies against EGFR
Malignant cells have an increased activity in a variety of
signal transport systems compared with normal cells.
Growth factors and their receptors are important for
normal cellular functions as cellular growth, prolifera-
tion, differentiation, angiogenesis and cell death. Several
subclasses of tyrosine kinase receptors and their ligands
have been isolated and among these are the EGFR and
ligands (epidermal growth factor and transforming
growth factor-a). Once a ligand binds to the extra-
cellular domain of EGFR, receptor dimerization occurs
and down-stream signalling cascades are activated.
Antibodies bind to EGFR with high afﬁnity and
prevent the binding of the natural ligands. This results in
reduced receptor activated tyrosine kinase activity and
subsequently to, for example, reduced cell proliferation,
cell survival and cell invasion.
Efﬁcacy and safety of Cx in mCRC
Cx is a chimeric IgG1 mAb that binds to the
extracellular ligand-binding domain of the EGFR with
a 5- to 10-fold greater afﬁnity than its natural ligands.
The efﬁcacy of Cx has been proven in third-line therapy,
but phase III studies are not yet mature in the ﬁrst- and
second-line line setting and therefore, we will begin our
review with third-line data.
Second- or third-line therapy
Preclinical and clinical studies have shown that Cx has
activity as a single-agent and synergistic activity in
combination with chemotherapy (Veronese and
O’Dwyer, 2004; Nygren et al., 2005; Stern and
Herrmann, 2005; Arnold et al., 2006; Saunders and
Iveson, 2006; Van Cutsem et al., 2006). In a phase II
Role of antibody therapy
P Pfeiffer et al
3667
Oncogene
study of 57 patients with irinotecan-refractory mCRC,
Cx alone produced a RR of 8.8% (Saltz et al., 2004), but
in combination with irinotecan the RR was as high as
22.5% (Saltz et al., 2001).
These encouraging results were conﬁrmed in the pivotal
randomized BOND I trial (Cunningham et al., 2004). In
BOND I, 329 patients whose disease had progressed
during or within 3 months after treatment with an
irinotecan-based regimen and whose tumors expressed
any level of EGFR were randomized to receive either Cx
(400mg/m2 loading dose, followed by 250mg/m2 weekly)
alone (111 patients) or Cx (as above) in combination with
irinotecan (same schedule as before; 218 patients). The
combination signiﬁcantly increased RR from 11 to 23%
and prolonged TTP from 1.5 to 4.5 months, but signiﬁcant
prolongation of OS was not seen, perhaps because the
study was not designed to show a survival difference or
perhaps due to crossover and use of CxIri as salvage
therapy at the time of PD. In 56 patients progressing on
Cx alone, the addition of irinotecan resulted in two partial
responses. Subgroup analyses indicated preserved efﬁcacy
for the combination for patients having prior oxaliplatin
treatment (65% of patients).
One of the criticisms of the BOND I study was the
lack of a control group. Therefore, a large phase III
study (NCIC-CO.17) was conducted by the National
Cancer Institute of Canada Clinical Trials Group
(NCIC CTG) in collaboration with the Australasian
Gastro-Intestinal Trials Group (AGITG). A total of 572
patients pretreated with irinotecan and oxaliplatin were
randomized to the BSC or Cx monotherapy. No data
have been presented yet, but a press release on 6
November 2006 stated that Cx did improve OS.
The multinational MABEL study was designed to
investigate irinotecan and Cx in a larger community
practice (Wilke et al., 2006). More than 1100 patients
with EGFR-detectable and irinotecan refractory mCRC
(69% also pretreated with oxaliplatin) received Cx in
combination with three different irinotecan schedules
(125mg/m2 weekly for 4/6 weeks, 180mg/m2 every 2
weeks or 350mg/m2 every 3 weeks). For all irinotecan
regimens, comparable RR, TTP, OS and toxicity were
seen. Overall RR was 20%, median TTP was 3.3 months
and median OS was 9.2 months, clearly conﬁrming in a
wider setting the efﬁcacy and safety of CxIri.
Since January 2005, third-line therapy with CxIri in
patients with mCRC resistant to FU/FA, irinotecan and
oxaliplatin (EGFR status was not mandatory) has been
offered at four departments in Denmark. The efﬁcacy
and toxicity in the ﬁrst 65 consecutive patients (Pfeiffer
et al., 2007b) treated at three departments were
registered and it was conﬁrmed in a general population
that salvage therapy with Cx and irinotecan is effective
in patients pretreated with irinotecan and oxaliplatin.
Almost identical results were found in an Italian study
with 55 patients (Vincenzi et al., 2006c).
A combination of Cx and oxaliplatin has been
investigated in patients having progressed on oxaliplatin
and on Cx plus irinotecan, but due to lack of response in
the ﬁrst 12 patients, the study was prematurely
terminated (Vincenzi et al., 2006b).
A randomized second-line study (EXPLORE) com-
pared FOLFOX with or without Cx. This study was
also prematurely stopped after inclusion of 102 patients
of the planned 1100 patients due to recent change in
clinical practice resulting in the replacement of irinote-
can with oxaliplatin in the ﬁrst-line setting in many
institutions. Safety analysis has been presented, but
there was no relevant therapeutic beneﬁt (Jennis et al.,
2005).
As a result of the BOND I study, the combination of
CxIri was approved for patients with irinotecan-
resistant disease in US in February 2004. In June
2004, Erbitux was approved by EMEA for the following
indication: ‘Erbitux in combination with irinotecan is
indicated for the treatment of patients with EGFR-
expressing metastatic colorectal cancer after failure of
irinotecan-including cytotoxic therapy’ (Nygren et al.,
2005).
First-line therapy
Several small and preliminary reported phase II trials
(Rougier et al., 2004; Dittrich et al., 2006; Folprecht
et al., 2006; Andre et al., 2007) have shown a promising
activity for chemotherapy–Cx combinations, but there
are not yet mature and reliable data available from
phase III studies. In these single-arm phase II studies,
combinations with irinotecan- or oxaliplatin-based
chemotherapy are well tolerated and active with RR
ranging from 45 to 81% and OS ranging from 23
months to more than 30 months (Table 4).
At the ASCO 2006 annual meeting, a two-by-two
randomized study from the CALGB group (randomiz-
ing chemonaive patients to either FOLFOX or FOL-
FIRI, with or without Cx) was presented (Venook et al.,
2006). This trial was also prematurely closed (after Bv
registration), but 238 patients were evaluable for
efﬁcacy. There was no difference in RRs for FOLFOX
vs FOLFIRI. Chemotherapy in combination with Cx
signiﬁcantly increased RR from 33 to 49%.
Prelimary data from two small randomized phase II
studies (Borner et al., 2006; Heinemann et al., 2006)
were also presented. One study showed that addition of
Cx to XELOX increased RR (from 27 to 43%) and
another study showed that the combination of XELOX
and Cx increased RR from 42 to 66% compared with
XELIRI and Cx.
Efﬁcacy results from randomized phase III trials
comparing FOLFIRI (CRYSTAL) or FOLFOX with or
without Cx in ﬁrst-line setting have to be awaited for a
deﬁnitive conclusion.
Efﬁcacy and safety of Pa in mCRC
Pa is a fully human anti-EGFR IgG2 mAb. In contrast
to IgG1 antibodies (e.g., Cx), Pa does not stimulate
antibody-dependent cell-mediated cytotoxicity (ADCC).
Clinical trials have documented efﬁcacy of Pa as
monotherapy (Malik et al., 2005; Peeters et al., 2006). In
a large phase II study, 148 pretreated patients with
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known EGFR overexpression were treated with Pa
2.5mg/kg i.v. weekly (Malik et al., 2005). A partial
response was observed in 9% of patients and disease
control in 29%, median TTP was 3.1 months and
median OS was 8.7 months. Pa was well tolerated, only
7% had skin toxicity grade III and only 3% had to
discontinue treatment due to toxicity. Only one patient
experienced infusion reaction, but it was possible to
retreat the patient in subsequent cycles.
A subsequent phase III trial was conducted to
compare efﬁcacy and safety of Pa plus BSC to BSC
alone in 463 patients with mCRC resistant to oxaliplatin
and irinotecan (Peeters et al., 2006). As in the BOND I
study, one of the inclusion criterias was EGFR positive
tumors (EGFR expression in X1% of tumor cells).
Patients received Pa 6mg/kg every 2 weeks until PD and
cross-over was allowed for patients, who progressed on
BSC.
Patients treated with Pa obtained PR of 8% and
disease stabilization in 28%. Treatment with Pa resulted
in 46% decrease in progression rate (e.g., TTP was
increased from 30% to 49% at week 8). The signiﬁcant
improvement in TTP was demonstrated in all sub-
groups, and the improvement was independent of
EGFR status (Hecht et al., 2006b). The rate (174
of 232 patients or 75%) and timing (median 7 weeks) of
crossover from the BSC arm to receiving Pa, and the
antitumor activity observed after crossover (RR 10%),
likely confounded the ability to demonstrate a treatment
effect on OS.
Preliminary data have shown that a combination of
FOLFIRI with Pa was well tolerated and had activity as
ﬁrst-line treatment (Hecht et al., 2006a).
Based on these data, Pa (Vectibix) was approved by
FDA on 27 September 2006 for the treatment of patients
with mCRC resistant to FU/FA, oxaliplatin and
irinotecan.
Toxicity of Cx and Pa
Side effects are in general related to abundant amounts
of EGFR in normal tissues like the skin, mouth and
gastrointestinal tract (GI tract), but in addition, admin-
istration of antibodies also may give rise to immunologic
reactions.
Table 4 Most important studies with Cx in patients with mCRC
Author Regimen Phase n RR (%) TTP (months) OS (months)
Third-line therapy
Cunningham et al. (2004) Cx II 111 11 1.5 6.9
BOND I CxIri 218 23a 4.1a 8.5
Lenz et al. (2006) Cx II 346 12 1.5 6.6
Saltz et al. (2005) Cx+Bv II 35 23 6.9 —
BOND II Iri+Cx+Bv 39 39 8.5 —
Pfeiffer et al. Acta Oncol (2007b) CxIri II 65 20 5.4 10.4
Vincenzi et al. (2006) CxIri II 55 25 4.7 9.8
Wilke et al. (2006)
MABEL
CxIri Open 1147 20 — 9.2
Van Cutsem, ASCO GI (2007) Classic CxIri II 77 22 — —
EVEREST Escalating CxIri III 44 30 — —
Not presented yet Classic CxIri 45 13 — —
BSC III 285 — — —
NCIC-CO.17 Cx 287 — — —
Second-line therapy
Abubakr et al., ASCO (2006) Iri III 650 — — —
EPIC CxIri 650 — — —
Jennis et al. (2005) FOLFOX III 52 — 4.1 —
EXPLORE FOLFOX+Cx 50 — 4.4 —
First-line therapy
In combination with irinotecan
Rougier et al. (2004) FOLFIRI+Cx I/II 42 45 — 23
Folprecht et al. (2006) AIO/Iri+Cx I/II 21 67 9.9 33
In combination with oxaliplatin
Dittrich et al. ASCO GI (2007)
ACROBAT
FOLFOX+Cx II 42 81 12.3 30
Dittrich et al. (2006) FUFOX+Cx II 49 57 — 30.6
Randomized studies
Borner et al. (2006) XELOX II 37 27 — —
SAKK XELOX+Cx 37 43 — —
Heinemann et al. (2006) XELOX+Cx II 41 66 — —
AIO XELIRI+Cx 43 42 — —
Venook et al., ASCO (2006) FOLFOX/FOLFIRI III 121 38 — —
CALGB 80203 FOLFOX/FOLFIRI+Cx 117 52a — —
Abbreviations: Cx, cetuximab; OS, overall survival; RR, response rate; TTP, time to progression. aSigniﬁcant difference.
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The most frequently encountered side effect to
treatment with Cx (Saltz et al., 2004) and Pa (Gibson
et al., 2006) is a generally mild to moderate acne-like
rash in more than 80% of the patients. It consists of a
folliculitis often associated with pruritus. It is predomi-
nantly located to seborrheic areas in the face (like the
nose, cheek, chin and forehead) and the upper chest and
back. However, depending on the severity of the rash it
can be located anywhere but not in the palms and soles
(Busam et al., 2001; Robert et al., 2005). Typically, the
rash appears within 1–2 weeks after onset of therapy
with spontaneous improvement within the next 4–5
weeks (Busam et al., 2001; Cunningham et al., 2004;
Saltz et al., 2004). The skin reactions are fully reversible
within a couple of weeks after cessation of therapy
(Robert et al., 2005). There are no evidence-based
recommendations for treatment of cutaneous side
effects, but systemic antibiotics like tetracycline or
steroids, topical retinoids and vitamin K have been
used successfully on an empirical basis (Yamamoto
et al., 2004; Agero et al., 2006; Perez-Soler et al., 2006).
Another problematic, but less frequent, dermatologi-
cal side effect is paronychia often seen after 2–4 months
of Cx therapy (Saltz et al., 2004).
Curly, ﬁne or more brittle hair on the scalp and
extremities and slow growth of beard has been reported
(Van Doorn et al., 2002). In contrast, extensive growth
of both eyelashes and eyebrows has been reported after
long-time treatment with Cx (Bouche´ et al., 2005;
Robert et al., 2005).
Affection of EGFR in the GI tract may cause nausea
and diarrhea (Cunningham et al., 2004; Vincenzi et al.,
2006a) as well as oral aphthous ulcers (Busam et al.,
2001).
EGFR is strongly expressed in the kidney, particu-
larly in the ascending limb of the loop of Henle where
70% of ﬁltered magnesium is reabsorbed and as a result,
EGFR blockade may trigger hypomagnesemia. Grade
3–4 hypomagnesemia has been observed in as many as
25% of patients (Carson et al., 2005; Schrag et al., 2005;
Fakih et al., 2006) and may augment nausea and fatigue.
Oral supplementation may be ineffective, then i.v.
magnesium sulpfhate will easily normalize the condition
(Fakih et al., 2006).
No study has compared side effects of Cx and Pa, but
crosstrial comparison (Saltz et al., 2004; Saif and
Cohenuram, 2006) showed that the spectrum of side
effects are equivalent, but anaphylactic reactions are
probably more rarely seen with Pa.
Comparison of Cx and Pa
RR for Cx and Pa single agents (8–11%) are very similar
in pretreated patients (Cunningham et al., 2004; Malik
et al., 2005; Lenz et al., 2006; Peeters et al., 2006). There
was no improvement in median OS, neither in the
Peeters study nor in the BOND I study, but this lack of
difference may be caused by the fact that many patients
in both studies received salvage therapy upon PD.
Indirectly, data from these randomized studies and
data from studies evaluating efﬁcacy of third-line
chemotherapy in patients with oxaliplatin and irinote-
can resistant disease (Rosati et al., 2003; Lim et al.,
2005) indicate that a combination of irinotecan and Cx
increase median OS from 5–6 to 9–10 months in heavily
pretreated patients.
There is apparently no difference in the incidence or
grade of rash but there are some differences in rare
instances. Development of interstitial lung disease
(0.5%) and human antihuman antibodies have only
been reported in patients receiving Cx. Pa has a higher
afﬁnity for EGFR, but antibodies with high afﬁnities for
target receptors may bind stably to the ﬁrst-encountered
receptor (including normal tissues) and thus have
impaired tumor penetration properties (Adams et al.,
2001). Only Cx induce antibody-dependent cell-
mediated cytotoxicity that may add to efﬁcacy.
Pa can be administrated without hypersensitivity
premedication, and it is routinely administrated every
2 (or perhaps 3) weeks, which makes Pa an excellent
partner for combination chemotherapy.
However, a pharmacokinetic and pharmacodynamic
study showed no major differences between Cx standard
dose weekly and Cx double dose every second week
(Tabernero et al., 2006), and since November 2005, we
have routinely administered simpliﬁed CxIri as third-
line treatment every second week to patients with
mCRC (Pfeiffer et al., 2007a). In 40 consecutive
patients, efﬁcacy and toxicity were similar to results
obtained with standard CxIri.
Several ongoing trials are actual evaluating the
efﬁcacy of both Cx and Pa in combination with
chemotherapy and other targeted agents as ﬁrst-line
treatment, and as adjuvant therapy.
Cx and Pa have not been compared directly, but the
two antibodies seem to have comparable efﬁcacy and
toxicity as single agent and in combination with
chemotherapy in chemorefractory patients.
Predicting efﬁcacy of Cx and Pa
Costs of targeted therapies warrant the selection of
patients that actually beneﬁt from the therapy. To date,
no predictive markers are in routine use, but several
promising candidates have been identiﬁed. Among these
are immunohistochemistry (IHC) and ﬂuorescence in situ
hybridization in pre-treatment tumor biopsies, the
development of skin rash, changes of biomarkers in the
skin or mutations in EGFR.
Correlation of survival with rash. In BOND I, patients
treated with CxIri and developing severe skin rash, RR
was 55%, TTP was 8.2 months and median OS was 13.7
months, respectively, and the degree of rash as a
predictive marker for RR and OS has been conﬁrmed
in many studies (Lenz et al., 2006; Pfeiffer et al., 2007b).
IHC and FISH in pre-treatment tumor biopsies. Ap-
proximately 75% of all colorectal carcinomas stain positive
for the EGFR (Salomon et al., 1995). In BOND I, efﬁcacy
for both CxIri and Cx alone was unrelated to percentage of
EGFR-expressing cells and staining intensity.
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Before approval of Cx, a multicenter study was
initiated to determine the activity of Cx in mCRC
refractory to both irinotecan and oxaliplatin (Lenz
et al., 2006). The aim of the study was to obtain more
information on the toxicity, but also to relate efﬁcacy to
EGFR gene mutations and gene ampliﬁcation. The RR
in 346 patients was 12%, TTP was 1.4 months and
OS was 6.6 months. RR and OS were strongly related
to skin rash. Interestingly, out of nine erroneously
EGFR-negative patients enrolled, two had partial
remissions.
Recent retrospective studies (Chung et al., 2005;
Hebbar et al., 2006) conﬁrmed activity of CxIri or Cx
alone in EGFR negative mCRC, and the practice of
testing EGFR status by IHC to select for Cx (or Pa)
therapy is clearly inappropriate and other predictive
tests are needed (Meropol, 2005; Nygren et al., 2005;
Hecht et al., 2006b). Furthermore, the expression in
primary tumors does not necessarily reﬂect or predict
the expression in metastatic sites (Scartozzi et al., 2004).
Perhaps the level of activated, phosphorylated EGFR
is more important than the total EGFR level (Ciardiello
and Tortora, 2003; Luo et al., 2005). In a small study,
with just 23 patients with irinotecan-resistent mCRC,
high expression of phosphorylated EGFR was a
predictive factor for high RR after to Cx (Personeni
et al., 2005).
Then, why does IHC not predict for activity of Cx?
First of all, EGFR positivity is relative and highly
dependent of the antibody used, the type of tissue
ﬁxation and the duration of storage (Grabau et al.,
1998). Secondly, tumor heterogeneity may play a role,
and ﬁnally the general assumption that an increased
number of receptors may lead to a greater degree of
clinical activity may be wrong. It is necessary to look in
greater detail at the target: activated EGFR, activation
of the downstream cascade, co-activation of other
related receptors or gene ampliﬁcation of the receptors
in question (Shia et al., 2005). In a small study with 31
patients receiving Cx or Pa, eight of nine responders had
ampliﬁcation of EGFR, whereas this was only the case
in one of 21 non-responders (Moroni et al., 2005).
Mutations. With the discovery of the prognostic
importance of mutations in the kinase domain of EGFR
for the efﬁcacy of kinase inhibitors in lung cancer
(Lynch et al., 2004; Paez et al., 2004), it was reasonable
to assume the same inﬂuence in colorectal carcinomas.
However, the presence of mutations in exon 18, 19 and
21 of the kinase domain (Barber et al., 2004; Moroni
et al., 2005; Tsuchihashi and Khambata-Ford, 2005;
Lenz et al., 2006) and mutation in the external part of
EGFR (Azuma et al., 2006) is very rare in CRCs
suggesting that EGFR mutations are not critical for
efﬁcacy of EGFR inhibition.
Other biomarkers. The absence of predictive markers
has increased the focus of other parts of signaling
pathways related to the EGFR system. No clinical data
are available, but at a preclinical level, it was found that
high gene expression of VEGF was associated with
resistance to EGFR inhibition (Vallbohmer et al., 2005).
In line with these data, long-lasting reduced levels of
serum VEGF was found upon treatment with Cx
(Vincenzi et al., 2006b). These preliminary data might
be important for the future combination of targeted
drugs like Bv, Cx and Pa.
Optimal dosage and schedule of Cx
Phase I studies (Baselga et al., 2000; Humblet et al.,
2005) have established the standard dose of Cx (loading
dose 400mg/m2 followed by weekly doses of 250mg/m2)
used in the majority of clinical trials.
Cx is administered weekly but preliminary data
suggest that Cx 500mg/m2 can be safely and effectively
be administered every second week (Tabernero et al.,
2006; Pfeiffer et al., abstract accepted for ASCO GI
2007a).
In the EVEREST study, all patients received standard
dose CxIri for 3 weeks. Patients with no or mild rash
(grade 0 or 1) were then randomized to continue
standard CxIri or CxIri with increasing dose of Cx.
The higher dose of Cx (up to 500mg/m2 weekly) was
generally well tolerated with slightly increased skin
toxicity as the only extra side effect and these data seems
to be supported by preliminary data from a phase I
study in multiple tumor types (Ho et al., 2006).
Recently, the ﬁrst efﬁcacy data for the EVEREST study
was presented (Van Cutsem et al., 2007b). Patients
treated with an increased dose of Cx had a doubling of
RRs (30 vs 13%), but data on TTP and OS are awaited
before this strategy can be recommended in routine
practice.
Combination of targeted therapies
Inhibition of the EGFR is a promising concept and it is
tempting to combine inhibition of the extracellular part
of EGFR with inhibition of the tyrosine kinase domain
– that is, combine antibody therapy with tyrosine kinase
inhibitors. Some preclinical studies (Huang et al., 2004;
Matar et al., 2004) but not all (Cunningham et al., 2006)
showed synergistic effect, but solid clinical data are
lacking.
There is a reliable rationale for combining VEGF and
EGFR inhibitors (Vallbohmer et al., 2005; Vincenzi
et al., 2006b). Preclinical studies conﬁrmed a synergistic
growth inhibition (Morelli et al., 2006; Tonra et al.,
2006) and preliminary clinical data have already veriﬁed
efﬁcacy of the combination (Saltz et al., 2005). The
BOND II trial was a randomized phase II trial
(combination of Cx and Bv with or without irinotecan),
but it was sadly preliminary stopped due to poor accrual
after inclusion of only 74 patients with irinotecan-
resistent mCRC (Table 3). High RR (23 and 39%) and
long TTP (6.9 and 8.5 months) without any unexpected
toxicity are very encouraging in these pretreated
patients, especially if results are weighed against BOND
I data (Table 4). These promising data are the basis for
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large ongoing phase III trials evaluating efﬁcacy of
modern chemotherapy in combination with Cx or Pa
and Bv.
Surgery and antibody therapy
Presently liver-resection offers the best chance of cure in
patients with resectable liver metastases, and non-
randomized studies indicate that comparable results
can be obtained following neo-adjuvant chemotherapy
in patients with initially unresectable liver metastases
(Adam et al., 2004). In phase III studies evaluating
doublets, a resection rate of 5–10% is often found. An
improved RR will hopefully result in even more curative
intended resections. Compared to historical data,
addition of antibodies to chemotherapy has increased
the resection rate (Rougier et al., 2004; Folprecht et al.,
2006; Andre et al., 2007), but presently it is not known
for sure whether the higher resection rate is caused by
more effective therapy or simply a matter of selection
and more experienced surgeons. In an excellent review
(Folprecht et al., 2005), it was found that 24–54% of
patients with non-resectable liver metastases became
resectable following chemotherapy, compared with 1–
26% of patients in trials that included non-selected
patients with mCRC. A strong correlation was found
between RRs and the resection rate and ‘resectability’ as
a novel end point in mCRC was suggested.
However, in several of the above-mentioned small
phase II studies, a doubling of resection rate has been
observed. If these data can be conﬁrmed in large studies,
there is a real chance that not only median survival but
also long-term survival will be inﬂuenced.
EGFR therapy in conjunction with surgery must be
considered very carefully as it is demonstrated that
EGFR regulates multiple facets of wound healing,
including inﬂammation, wound contraction, prolifera-
tion, migration and angiogenesis (Repertinger et al.,
2004). In head and neck cancer, a small study with eight
patients (Harari et al., 2003) receiving elective neck
dissection after curative intended radiotherapy in
combination with Cx, the length of hospital stay was
not prolonged and no postoperative complications was
found. In phase II studies in mCRC, a number of
patients had R0 liver-resection after neo-adjuvant
therapy without extra comlications reported (Rougier
et al., 2004; Tabernero et al., 2004; Folprecht et al.,
2006).
Preclinical studies have shown that inhibition of
angiogenesis may impair wound healing (Howdieshell
et al., 2001). In clinical trials/observational studies
wound healing complication is reported to occur in
0.3–5.6% of patients receiving chemotherapy and Bv
(Van Custsem et al., 2007a; Hochster et al., 2006;
Kozloff et al., 2006).
A pooled analysis of AVF 2107 and AVF 2192
(Scappaticci et al., 2005) assessed wound healing
complications in patients who underwent surgery 28–
60 days before study treatment (patients who had
undergone major surgery within 28 days were not
eligible for enrolment). The risk of wound healing
complications was not signiﬁcantly increased in patients
receiving Bv at least 4 weeks after surgery. In addition,
surgical complications in patients who underwent major
surgery (5.6% of patients receiving chemotherapy alone,
but 12% of patients receiving Bv) during study
treatment were evaluated. Wound healing complication
was increased from 3.4 to 13% in patients receiving
treatment with Bv if surgery was performed within 60
days after last treatment. In accordance with these data,
it was recommended waiting at least 8 weeks after last
dose of Bv based on pharmacokinetic data (Ellis et al.,
2005).
In a pilot study, eight of nine patients receiving neo-
adjuvant XELOX and Bv underwent liver resection for
synchronous liver metastases (Gruenberger et al., 2006).
Therapy with Bv was discontinued 5 weeks before
surgery and restarted 5 weeks after surgery. The authors
found no extra complications compared with their
previous data evaluating chemotherapy alone before
surgery. Yet this pilot study included a small number of
patients, and therefore, more clinical data are needed
before any ﬁnal conclusion can be made.
Implantation of venous access device shortly before
starting Bv did not increase the risk of wound healing/
bleeding (Van Cutsem et al., 2007a)
Cost
More progress has been made in increasing the duration
of survival of patients with mCRC in the past 5 years
than in most other cancers. We have seen approval of
irinotecan, oxaliplatin, Cx, Bv and recently Pa, and
these newer therapies are much more expensive than
FU/FA (Schrag, 2004; Paramore et al., 2006).
In a recent study (Paramore et al., 2006), the mean
monthly disease-related cost almost tripled from 1998
($4200) to 2004 ($11 100). Monthly disease-related costs
were similar in the diagnostic phase ($12 200) and death
phase ($12 300), but were signiﬁcantly lower in the
treatment phase ($4700). Patients with longer survival
thus have a lower average monthly cost. The study
points out that the economic impact of mCRC is
substantial and increasing over time and that monthly
cost almost tripled from 1998 to 2004.
Because of substantial increase in costs, questions and
discussions about cost-effectiveness of new therapies are
needed. Cost-effectiveness analysis is a tool that can
help to shift away from or avoid therapies that produce
too little beneﬁt at too high cost. Presently, there is no
consensus regarding the appropriate threshold value,
but a range of $50 000–100 000 per gained life year is
commonly used in the United States (Hillner et al., 2005)
and in UK, a threshold of d30 000 (approximately
$55,000) has been suggested (Miners et al., 2005).
N9741 demonstrated that FOLFOX was superior to
the previous standard of care in the United States, IFL
(Goldberg et al., 2004). Compared to IFL a post hoc
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analysis revealed that FOLFOX increased average cost
of almost $30 000 corresponding to approximately
$80 000 per life year gained and $110 000 per quality-
adjusted life year (Hillner et al., 2005). The authors
concluded that FOLFOX provided considerable bene-
ﬁts, however, the substantial additional costs fell into
the upper range of commonly accepted oncology
interventions.
In August 2006, the UK’s National Institute of
Clinical Excellence decided not to recommend the use
of Bv and Cx in mCRC based on the cost-effectiveness,
arguing that both drugs are too expensive. The decision
prompted outcries from charities and oncologists and
appeals have already been launched before the ﬁnal-
stage draft guidance comes into effect.
Final remarks
Medical treatment of mCRC has changed dramatically
in the past 5 years. Which patient should receive
targeted therapy in combination with chemotherapy
taking into account efﬁcacy, toxicity and costs? There is
no clear-cut answer that may differ from department to
department or from country to country.
Both the ‘new’ targeted drugs and the ‘old’ cytotoxic
agents have contributed to a substantial improved
outcome for our patients. Presently, there are several
appropriate treatment options without any single optimal
regimen and this has made the treatment decision more
complex, but at the same given room for individualized
treatment. The best choice for a given patient must take
into account, for example, age, performance status,
symptoms, co-morbidity and whether the tumor is
potential resectable after neo-adjuvant therapy:
The contribution from antibodies is important but
still small in absolute terms and at a price that will be
difﬁcult to handle in some health-care systems. There-
fore, selection of patients with a higher chance of
responding to a speciﬁc treatment is very important and
tumor, serum and plasma must be collected prospec-
tively along with clinical data to look for predictive
markers.
Randomized studies have consistently shown that
addition of Bv to chemotherapy prolongs TTP with 3–4
months and OS with 4–6 months in the ﬁrst-line
treatment and if a drug prolongs median survival for
4–6 months, patients should deﬁnitely be offered this
treatment. It remains to be proven that Bv also will add
4–6 months to the efﬁcacy of ‘optimal chemotherapy
regimens’. However, for many patients, Bv should be
integrated into the standard ﬁrst-line therapy but ‘best
chemotherapy’ (e.g., FOLFOX or FOLFIRI) may be a
reasonable alternative.
Presently, it is not known whether Bv should be
continued in combination with second-line chemother-
apy, but this question is currently being investigated.
The high RR, resection rate and very long OS of
selected patients receiving Cx and chemotherapy in ﬁrst
line phase II trials are very promising, but conﬁrmatory
randomized trials must be awaited before ﬁnal conclu-
sions.
There is strong evidence for treatment of patients with
Cx (or Pa) and irinotecan after failure of irinotecan- and
oxaliplatin-based therapies. The high RR and long OS
in ﬁrst-line phase II trials are very promising, but
conﬁrmation in randomized trials are required. The
practice of testing EGFR status by IHC to select for
EGFR antibody therapy is clearly inappropriate and
should no longer be used.
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